O

Oculis Holding AG
NASDAQ:OCS

Watchlist Manager
Oculis Holding AG
NASDAQ:OCS
Watchlist
Price: 20 USD 0.15% Market Closed
Market Cap: 1.2B USD

Oculis Holding AG
Investor Relations

Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improve eye care. The company is headquartered in Zug, Zug and currently employs 28 full-time employees. The firm is focused on the development of eye disease treatment for ophthalmology. The company includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The firm have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Dr. Riad Sherif M.B.A., M.D.
CEO & Director
No Bio Available
Ms. Sylvia Cheung
Chief Financial Officer
No Bio Available
Ms. Gudrun Bachmann Ph.D.
Chief Technology Officer
No Bio Available
Dr. Ramin Tadayoni M.D., Ph.D.
Chief Scientific Officer
No Bio Available
Mr. Daniel S. Char J.D.
Chief Legal Officer
No Bio Available
Ms. Virginia R. Dean
Chief Human Resources Officer
No Bio Available
Mr. Páll Ragnar Jóhannesson
Chief Business Officer
No Bio Available
Ms. Rebecca Weil
Chief Commercial Officer
No Bio Available
Dr. Snehal Shah Pharm.D.
President of Research & Development
No Bio Available
Dr. Sharon Klier M.D., M.P.H.
Chief Development Officer
No Bio Available

Contacts

Address
ZUG
Zug
Bahnhofstrasse 7
Contacts
+41588100182
oculis.com